8W9J image
Entry Detail
PDB ID:
8W9J
Keywords:
Title:
Crystal structure of human CLEC12A ectodomain complexed with 50C1 Fab
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2023-09-05
Release Date:
2024-03-06
Method Details:
Experimental Method:
Resolution:
3.50 Å
R-Value Free:
0.29
R-Value Work:
0.25
R-Value Observed:
0.25
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:C-type lectin domain family 12 member A
Chain IDs:E (auth: C), F (auth: D)
Chain Length:203
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Anti-human CLEC12A antibody 50C1 heavy chain
Chain IDs:B (auth: H), D (auth: B)
Chain Length:223
Number of Molecules:2
Biological Source:Mus musculus
Polymer Type:polypeptide(L)
Description:Anti-human CLEC12A antibody 50C1 light chain
Chain IDs:A (auth: L), C (auth: A)
Chain Length:216
Number of Molecules:2
Biological Source:Mus musculus
Ligand Molecules
Primary Citation
Crystal structure of the complex of CLEC12A and an antibody that interferes with binding of diverse ligands.
Int.Immunol. 36 279 290 (2024)
PMID: 38386511 DOI: 10.1093/intimm/dxae006

Abstact

C-type lectin receptors (CLRs) are a family of pattern recognition receptors, which detect a broad spectrum of ligands via small carbohydrate-recognition domains (CRDs). CLEC12A is an inhibitory CLR that recognizes crystalline structures such as monosodium urate crystals. CLEC12A also recognizes mycolic acid, a major component of mycobacterial cell walls, and suppresses host immune responses. Although CLEC12A could be a therapeutic target for mycobacterial infection, structural information on CLEC12A was not available. We report here the crystal structures of human CLEC12A (hCLEC12A) in ligand-free form and in complex with 50C1, its inhibitory antibody. 50C1 recognizes human-specific residues on the top face of hCLEC12A CRD. A comprehensive alanine scan demonstrated that the ligand-binding sites of mycolic acid and monosodium urate crystals may overlap with each other, suggesting that CLEC12A utilizes a common interface to recognize different types of ligands. Our results provide atomic insights into the blocking and ligand-recognition mechanisms of CLEC12A and leads to the design of CLR-specific inhibitors.

Legend

Protein

Chemical

Disease

Primary Citation of related structures